Showing 1 - 19 results of 19 for search '(((( 5 ng decrease ) OR ( 50 n decrease ))) OR ( 10 ((ng decrease) OR (we decrease)) ))~', query time: 0.41s Refine Results
  1. 1

    Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

    Published 2022
    “…The antiproliferative activity of the novel <i>mono</i>- and <i>bis</i>(dimethylpyrazolyl)-<i>s</i>-triazine derivatives was studied against three cancer cell lines, namely, MCF-7, HCT-116, and HepG2. <i>N</i>-(4-Bromophenyl)-4-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine <b>4f</b>, <i>N</i>-(4-chlorophenyl)-4,6-bis­(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-1,3,5-triazin-2-amine <b>5c</b>, and 4,6-<i>bis</i>(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(4-methoxyphenyl)-1,3,5-triazin-2-amine <b>5d</b> showed promising activity against these cancer cells: <b>4f</b> [(IC<sub>50</sub> = 4.53 ± 0.30 μM (MCF-7); 0.50 ± 0.080 μM (HCT-116); and 3.01 ± 0.49 μM (HepG2)]; <b>5d</b> [(IC<sub>50</sub> = 3.66 ± 0.96 μM (HCT-116); and 5.42 ± 0.82 μM (HepG2)]; and <b>5c</b> [(IC<sub>50</sub> = 2.29 ± 0.92 μM (MCF-7)]. …”
  2. 2

    Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

    Published 2022
    “…The antiproliferative activity of the novel <i>mono</i>- and <i>bis</i>(dimethylpyrazolyl)-<i>s</i>-triazine derivatives was studied against three cancer cell lines, namely, MCF-7, HCT-116, and HepG2. <i>N</i>-(4-Bromophenyl)-4-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine <b>4f</b>, <i>N</i>-(4-chlorophenyl)-4,6-bis­(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-1,3,5-triazin-2-amine <b>5c</b>, and 4,6-<i>bis</i>(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(4-methoxyphenyl)-1,3,5-triazin-2-amine <b>5d</b> showed promising activity against these cancer cells: <b>4f</b> [(IC<sub>50</sub> = 4.53 ± 0.30 μM (MCF-7); 0.50 ± 0.080 μM (HCT-116); and 3.01 ± 0.49 μM (HepG2)]; <b>5d</b> [(IC<sub>50</sub> = 3.66 ± 0.96 μM (HCT-116); and 5.42 ± 0.82 μM (HepG2)]; and <b>5c</b> [(IC<sub>50</sub> = 2.29 ± 0.92 μM (MCF-7)]. …”
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

    Minimum concentration of Amphotericin B in serum according to the formulation, dose, and daily or prolonged intermittent therapeutic regimen by Leticia Aparecida Schiave (8438409)

    Published 2020
    “…The geometric mean Cmin tended to decrease with a reduction in the dose and frequency of intermittent L-AmB infusions: 357 ng/mL (100 mg 4 to 5 times/week) > 263 ng/mL (50 mg 4 to 5 times/week) > 227 ng/mL (50 mg 1 to 3 times/week). …”
  11. 11
  12. 12
  13. 13

    Data_Sheet_1_Identification of novel small molecule inhibitors of twin arginine translocation (Tat) pathway and their effect on the control of Campylobacter jejuni in chickens.pdf by Loïc Deblais (5620073)

    Published 2024
    “…These selected eight Tat inhibitors cleared all tested Campylobacter strains (n = 12) at >10ng/mL in the presence of 0.5 mM CuSO<sub>4</sub>in vitro. …”
  14. 14

    I-R-Polar-Negative-0902 by Sheng-Yuan Ho (16909464)

    Published 2023
    “…The mass spectrometer was configured as follows: negative ion mode, capillary voltage of 2 kV, source temperature of 120°C, desolvation gas N2 at 900 L/h at 550°C, cone gas N2 at 15 L/h, capillary voltage of 2.8 kV, cone voltage of 40 V, and time-of-flight mass spectrometry (TOF MS) scan range of 50 to 1000 m/z. …”
  15. 15

    Mitochondrial genome sequencing with short overlapping amplicons on MiSeq FGx system by Yang Xin (286771)

    Published 2022
    “…Cross-reactivity was observed with 1 ng primate DNA and 10ng non-primate DNA but could be easily distinguished. …”
  16. 16
  17. 17

    Supplementary Material for: Identification of risk factors associated with metabolic dysfunction-associated steatotic liver disease in psoriatic patients by Küçük K. (20178678)

    Published 2024
    “…Biochemical analysis revealed significantly higher C-peptide level in patients with MASLD compared with patients without MASLD (2.5 vs 1.6ng/ml, p=0.036). Moreover, MASLD patients were found to have a lower HDL level and higher glycemia, triglyceridemia, cholesterol and LDL levels than non-MASLD patients. 16.3% of patients with MASLD had fibrosis stage ranging from F2 to F4 based on liver stiffness measurement compared with only 10.6% of patients without MASLD. …”
  18. 18
  19. 19